ADMA vs. INBX, NMRA, FDMT, SANA, AUTL, RXRX, FUSN, TWST, TARS, and SRRK
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Inhibrx (INBX), Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Recursion Pharmaceuticals (RXRX), Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Tarsus Pharmaceuticals (TARS), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
ADMA Biologics (NASDAQ:ADMA) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
ADMA Biologics presently has a consensus target price of $7.88, indicating a potential upside of 14.80%. Inhibrx has a consensus target price of $27.00, indicating a potential downside of 21.24%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe ADMA Biologics is more favorable than Inhibrx.
ADMA Biologics has higher revenue and earnings than Inhibrx. ADMA Biologics is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.
ADMA Biologics has a net margin of -10.94% compared to Inhibrx's net margin of -13,408.95%. ADMA Biologics' return on equity of 0.49% beat Inhibrx's return on equity.
ADMA Biologics received 370 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 71.48% of users gave ADMA Biologics an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
In the previous week, ADMA Biologics had 5 more articles in the media than Inhibrx. MarketBeat recorded 6 mentions for ADMA Biologics and 1 mentions for Inhibrx. Inhibrx's average media sentiment score of 1.63 beat ADMA Biologics' score of 0.61 indicating that Inhibrx is being referred to more favorably in the news media.
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 25.8% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
ADMA Biologics beats Inhibrx on 13 of the 19 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
